ALD-ALLY is a call to action for advancing the science and care of patients with metabolic-dysfunction and alcohol-associated liver disease (MetALD and ALD)

Program Overview


We’re excited to announce the 2nd annual ALD-ALLY (Alcohol-associated Liver Disease patients deserve ALcohol LiteracY) Conference on April 10, 2026.

This one-day CME conference is designed to meet the educational needs of healthcare professionals. It will facilitate intimate dialogues among experts, providers, and stakeholders, aiming to enhance collaboration, advocacy, research, and care delivery for patients with Alcohol-Associated Liver Disease (ALD). Our goal is to foster meaningful discussions that will advance the field of ALD and MetALD.

ALD-ALLY is a call to action for advancing the science and care of patients with alcohol-associated liver disease (ALD) by gathering international experts to lead a multidisciplinary dialogue among a wide spectrum of stakeholders. Our intent is for ALD-ALLY to become the premier annual ALD meeting focused on actionable initiatives and collaborations through state-of-the-art lectures, academic debates, and patient advocacy in a lively in-person, discussion-encouraged setting. The conference will kick off with the exhibits open from breakfast until the conclusion of the evening reception.  A light reception will take place in the exhibit hall immediately following the last presentation. All breaks will be held in the exhibit hall to encourage attendee engagement and foot traffic throughout the space.  Be an ALLY and join us in New York!

Learning Objectives

• Explore the details of high impact, practice-changing studies in MetLAD, ALD and AUD. 
• Discuss emerging concepts and future therapeutics in MetALD.
• Identify how genetics and biomarkers can guide personalized treatment plans for patients with Metabolic and Alcohol-associated Liver Diseases.
• Explore the application and impact of digital tools, such as wearables and remote monitoring, in enhancing the management of alochol-related health issues.
• Distinguish between fact and fiction regarding contraindications in medications for AUD in paitents with advanced MetALD or ALD.
• Target successful models of integrating care across inpatient and outpatient settings, emphasizing coordination and mulitdisciplinary collaboration.
• Discuss and understand the importance of integrating patient voices and experiences into the decision-making process to improve treatment adherence and outcomes.

Agenda Highlights

• Emerging Concepts and Therapies for MetALD
• Advances in Digital Care for ALD and MetALD
• Incorporating Genetics and Biomarkers in MASH, MetALD, and ALD Care
• High Impact Studies in AUD, ALD, and MetALD— Year in Review
• Innovations in Integrated Alcohol Care: Inpatient, Outpatient, and the Patient Voice
• Alcohol and MetALD Debates